Led by Shannon L. Maude, MD, PhD, researchers in the Maude Research Program are focused on developing and clinically evaluating new immunotherapies and targeted cancer therapies to treat children with high-risk and relapsed/refractory acute lymphoblastic leukemia (ALL). The long-term goal of the work conducted in this research program is to identify new pediatric ALL treatments that are more effective, less toxic and exhibit fewer side effect than existing cancer therapies.
Updated results from a global clinical trial of the CAR T-cell therapy for ALL reveal that children and young adults continued to show high rates of durable, complete remission of their disease.
Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein. Blood. 2015 Jul 30;126(5):629-39.
Qin H, Cho M, Haso W, Zhang L, Tasian SK, Oo HZ, Negri GL, Lin Y, Zou J, Mallon BS, Maude S, Teachey DT, Barrett DM, Orentas RJ, Daugaard M, Sorensen PHB, Grupp SA, Fry TJ.
Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. Blood. 2015 Mar 12;125(11):1759-67.
Maude SL, Dolai S, Delgado-Martin C, Vincent T, Robbins A, Selvanathan A, Ryan T, Hall J, Wood AC, Tasian SK, Hunger SP, Loh ML, Mullighan CG, Wood BL, Hermiston ML, Grupp SA, Lock RB, Teachey DT.
Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014 Oct 16;371(16):1507-17.
Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA.
